Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Conditions
Tobacco Use
Interventions
Personalized Smoking Cessation Facilitation Meetings, Personalized Smoking Cessation Pharmacotherapy, Personalized Text Messaging Support, SmokefreeVET, VA Quitline, Education about pharmacotherapy
Behavioral · Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional Results available

Improving Tobacco Treatment Rates for Cancer Patients Who Smoke

NCT04738643
Conditions
Cancer, Tobacco Use, Smoking, Nicotine Dependence
Interventions
Tobacco Use Treatment Service and Varenicline Management
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
Not listed
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Not listed Not applicable Interventional Accepts healthy volunteers

Treating Smokeless Tobacco Use in Rural Veterans

NCT02994082
Conditions
Smokeless Tobacco, Nicotine Dependence
Interventions
Tailored behavioral intervention, Behavioral activation for elevated depressive symptoms, Post-cessation weight gain management, Alcohol use risk reduction, Nicotine replacement therapy - transdermal nicotine patch, Nicotine replacement therapy - nicotine lozenge, Nicotine replacement therapy - nicotine gum, Bupropion sustained release, Varenicline, Combination nicotine replacement therapy, Combination nicotine replacement therapy + bupropion, Tobacco quit line, Educational materials
Behavioral · Drug
Lead sponsor
Mark Vander Weg
Federal
Eligibility
18 Years to 99 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Active, not recruiting Phase 3 Interventional

Optimizing Tobacco Use Treatment for PLWHA

NCT04176172
Conditions
HIV/AIDS, Nicotine Dependence
Interventions
Varenicline, Nicotine patch, Standard treatment, Standard treatment + Managed Problem Solving (MAPS) adherence intervention
Drug · Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Conditions
Smoking Cessation
Interventions
Standard Care (SC), Intensive Counseling (IC)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tailored Tobacco Quitline for Rural Veterans

NCT01592695
Conditions
Cigarette Smoking
Interventions
Nicotine replacement therapy - transdermal nicotine patch, Tailored behavioral intervention, Tobacco quit line referral, Nicotine replacement therapy - nicotine gum, Nicotine replacement therapy - nicotine lozenge, Bupropion Sustained Release, Varenicline, Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - transdermal nicotine patch + bupropion, Alcohol use risk reduction, Behavioral activation for the treatment of depression, Behavioral management of post-cessation weight gain
Drug · Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Recruiting Phase 3 Interventional Accepts healthy volunteers

Cannabis-Tobacco Co-Use Treatment Study

NCT06883162
Conditions
Tobacco Use Disorder, Tobacco Use Cessation, Cannabis Use, Cannabis Use Disorder, Marijuana Use
Interventions
Varenicline, Counseling, Psychosocial modules
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Cigarette Smoking, Tobacco Smoking, Tobacco Use Disorder
Interventions
Sustained Care, Standard Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Salem, Massachusetts • Pittsburgh, Pennsylvania
Conditions
Nicotine Dependence, Tobacco Use
Interventions
Nicotine replacement therapy - Transdermal nicotine patch, Nicotine replacement therapy - Nicotine gum, Nicotine replacement therapy - Nicotine lozenge, Bupropion, Varenicline, Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - Transdermal nicotine patch + bupropion, Tobacco quitline referral, Tailored behavioral intervention, Alcohol use risk reduction, Behavioral activation for depressive symptoms, Behavioral management of postcessation weight gain
Drug · Behavioral
Lead sponsor
Mark Vander Weg
Other
Eligibility
18 Years to 99 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Phase 4 Interventional Results available

Cannabis and Tobacco Co-use Study

NCT04228965
Conditions
Tobacco Use Disorder
Interventions
Varenicline, Contingency Management, Counseling
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 40 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Charleston, South Carolina • Florence, South Carolina • Pickens, South Carolina
Conditions
Cigarette Smoking
Interventions
Extended Care Management, Standard Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts